VivoSeq
Oncology

Gastric or Gastroesophageal Junction Adenocarcinoma

7

Pipeline Programs↗

2

Active Trials↗

6

Companies Involved↗

Gastric or Gastroesophageal Junction Adenocarcinoma is an early-stage landscape with 7 programs across 6 companies. The most active players are Phanes Therapeutics, Bristol-Myers Squibb, Teva.

Intelligence

Pipeline Metrics

Competitive Density

33/100

Pipeline Velocity

6/100

Mech. Concentration

33/100

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

P

Phanes Therapeutics

2 programs

PreclinicalBristol-Myers Squibb logo

Bristol-Myers Squibb

2 programs

PreclinicalTeva logo

Teva

1 program

PreclinicalJohnson & Johnson logo

Johnson & Johnson

1 program

PreclinicalMerck & Co. logo

Merck & Co.

1 program

PreclinicalAstraZeneca logo

AstraZeneca

1 program

Preclinical

Pipeline

Programs by Phase

Preclinical7

Spevatamig (PT886)

Phanes Therapeutics

Paclitaxel

Teva

Gemcitabine

Johnson & Johnson

Nab-Paclitaxel

Bristol-Myers Squibb

Pembrolizumab

Merck & Co.

Phase 1
No programs
Phase 2
No programs
Phase 3
No programs
Approved
No programs

Analysis

Modality Breakdown

88%

Small molecule

7 of 8 classified programs — the dominant modality here.

13%ALL OTHERSMonoclonal antibody113%

Small molecule leads; the ring shows all 8 classified programs, each share of the total. Modality classified for 89% of 9 pipeline programs.

Analysis

Trial Status

3

clinical trials

Recruiting1 · 33%
Completed1 · 33%
Not yet recruiting1 · 33%

Clinical Trials

Trial Activity

A Phase 1/2, Open-Label, Dose Escalation and Expansion Study With PT886 (Spevatamig) Followed by a Multi-cohorT Study in Patients With Advanced GastrIc, Gastroesophageal JuNction, Pancreatic Ductal or Biliary Tract AdEnocarcinomas of PT886, in Combination With ChemotherApy, and/or an Immune ChecKpoint Inhibitor. The TWINPEAK Study
Recruiting·PPhanes Therapeutics·Preclinical·NCT05482893·258 enrolled
Neoadjuvant Chemo-hypofractionated Radiotherapy Plus PD-1 Antibody (Tislelizumab) in Locally Advanced Resectable Gastric or Gastroesophageal Junction Adenocarcinoma
Completed·JJiangsu Cancer Institute & Hospital·Phase 2·NCT05941481·21 enrolled
A Prospective, Multicenter, Randomized Controlled Study of Neoadjuvant PD-1 Inhibitor Combined With SOX Chemotherapy With or Without Short-Course Radiotherapy (With Omission of Regional Lymph Node Irradiation) for Locally Advanced Upper Gastric or Gastroesophageal Junction Adenocarcinoma
Not yet recruiting·TTongji Hospital·Preclinical·NCT07674342·146 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)